SCHEMBL5669149

SCHEMBL5669149

CCCC(CNCc1ccc2c(c1)Cc1ccccc1-2)CNc1cc(=O)c2ccccc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MARS1 P56192 1/20 0.44
CYP19A1 P11511 1/20 0.37
CTSV O60911 1/20 0.36
CTSL P07711 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5668528 0.83 MARS1 (0.64) MARS1CTSVCTSL
SCHEMBL5668313 0.82 CTSV (0.52) MARS1CTSVCTSL
SCHEMBL6740398 0.81 MARS1 (0.45) MARS1
SCHEMBL5671067 0.81 MARS1 (0.46) MARS1
SCHEMBL5670265 0.79 MARS1 (0.44) MARS1CTSVCTSL
SCHEMBL5668198 0.79 MARS1 (0.51) MARS1
SCHEMBL5665610 0.79 MARS1 (0.43) MARS1
SCHEMBL5669073 0.77
SCHEMBL5668903 0.77 MARS1 (0.41) MARS1
SCHEMBL5670561 0.77 MARS1 (0.42) MARS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1351688-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2006-01-04 EP claimed
US-20040039017-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2004-02-26 US claimed
EP-1351688-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2003-10-15 EP claimed
WO-2002047687-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-20 WO claimed
US-20040039017-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039017-A1 Urotensin-II receptor antagonists UTS2R, NTSR2, PLAUR MARS1 2410/4885CYP19A1 3762/4885CTSV 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.